Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Tonga Healthcare Daily.
Press releases published on August 4, 2025
Catalyst Pharmaceuticals Appoints Daniel Curran, MD, to its Board of Directors
GlobeNewswire
·
August 4, 2025
CORAL GABLES, Fla., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced the appointment of Daniel Curran, MD, to its Board of Directors. Dr. Curran is a distinguished pharmaceutical …
Xenon to Report Q2 2025 Financial Results on August 11, 2025
GlobeNewswire
·
August 4, 2025
VANCOUVER, British Columbia and BOSTON, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for …
ARS Pharmaceuticals Announces Conference Call and Webcast for its Second Quarter 2025 Financial Results
GlobeNewswire
·
August 4, 2025
SAN DIEGO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to …
Mural Oncology Announces Second Quarter Financial Results and Provides Business Update
GlobeNewswire
·
August 4, 2025
Mural continues to explore strategic alternatives Estimates cash and cash equivalents of approximately $43 to $48 million at December 31, 2025, if it has not consummated a transaction or other strategic alternative by year end WALTHAM, Mass. and DUBLIN, …
Bioventus Enters into a New $400 Million Senior Secured Credit Agreement Lowering Interest Expense and Providing Increased Liquidity
GlobeNewswire
·
August 4, 2025
DURHAM, N.C., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it has entered into a $400 million Senior Secured Credit Agreement (the “ …
LifeMD to Participate in the Canaccord Genuity 45th Annual Growth Conference
GlobeNewswire
·
August 4, 2025
NEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced its participation in the Canaccord Genuity 45th Annual Growth Conference, which will be held August 12-14, 2025 at …
BioAtla to Announce Second Quarter 2025 Financial Results and Provide Business Highlights on August 7, 2025
GlobeNewswire
·
August 4, 2025
SAN DIEGO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today …
INmune Bio’s CaRe PC Trial of INKmune™ in Metastatic Castration-Resistant Prostate Cancer Meets Endpoints and Is Closed to Enrollment
GlobeNewswire
·
August 4, 2025
BOCA RATON, FL, Aug. 04, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immunology and inflammation company, is pleased to report that its Phase I/II trial (the “CaRe PC” trial) of INKmune™ for men with …
Praxis Precision Medicines Announces Positive, Best-in-Disease Topline Results in Patients with Focal Onset Seizures from the RADIANT Study of Vormatrigine
GlobeNewswire
·
August 4, 2025
Dosing with vormatrigine over 8 weeks led to 56.3% median reduction in seizure frequency Approximately 22% of patients reached 100% reduction in seizure frequency in the last 28 days on treatment Rapid and sustained response, with over 54% of patients …
Connect Appoints James Zanewicz as Chief Executive Officer to Shape the Next Chapter of Innovation Growth
GlobeNewswire
·
August 4, 2025
SAN DIEGO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Connect, the premier nonprofit organization in the San Diego innovation ecosystem established 40 years ago to cultivate life science and tech innovation communities, today announced the appointment of James …
Belite Bio to Host Webcast on August 11, 2025, to Discuss Second Quarter 2025 Financial Results
GlobeNewswire
·
August 4, 2025
SAN DIEGO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today …
Akebia Initiates Vafseo® (vadadustat) Post-Marketing Study in Conjunction with Large Dialysis Organization
GlobeNewswire
·
August 4, 2025
CAMBRIDGE, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the initiation of a post-marketing study …
MediWound to Report Second Quarter 2025 Financial Results
GlobeNewswire
·
August 4, 2025
MediWound to Report Second Quarter 2025 Financial Results Conference call and webcast scheduled for Thursday, August 14 at 8:30 a.m. Eastern Time YAVNE, Israel, August 4, 2025 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic …
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
August 4, 2025
SAN DIEGO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on …
XOMA Royalty Enters into Agreement to Acquire LAVA Therapeutics for Between $1.16 and $1.24 Per Share in Cash, Plus a Contingent Value Right
GlobeNewswire
·
August 4, 2025
EMERYVILLE, Calif. and UTRECHT, The Netherlands and PHILADELPHIA, Aug. 04, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (“XOMA Royalty”) (NASDAQ: XOMA) and LAVA Therapeutics N.V. (“LAVA”) (NASDAQ: LVTX) announced today they have entered a definitive …
Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy (DMD)
GlobeNewswire
·
August 4, 2025
- Data from the DELIVER registrational expansion cohort is expected in late 2025, with a potential BLA submission for U.S. accelerated approval anticipated in early 2026 - WALTHAM, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq …
Zevra Therapeutics Announces Details for Q2 2025 Financial Results Call
GlobeNewswire
·
August 4, 2025
CELEBRATION, Fla., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced it will report corporate …
Cassava Sciences Reports Positive Preclinical Study Evaluating Simufilam for TSC-Related Epilepsy
GlobeNewswire
·
August 4, 2025
Study in a TSC mouse model further demonstrates simufilam’s anti-seizure activity Study conducted in collaboration with TSC Alliance using a well-accepted Tsc1-knockout model First clinical study for simufilam in TSC-related epilepsy expected to begin in …
Artelo Biosciences Announces $9.475 Million At-the-Market Private Placement to Initiate Solana Treasury Strategy, Becoming First Publicly-Traded Pharmaceutical Company to Adopt SOL as a Core Reserve Asset
GlobeNewswire
·
August 4, 2025
Lead investor Bartosz Lipiński, previously Head of Engineering at Solana Labs, will serve as a technical partner CUBE selected to secure storage, staking, and active DeFi execution of Artelo’s digital asset treasury Artelo’s Board approves authorization to …
OraSure Appoints Anne Messing as Chief Commercial Officer
GlobeNewswire
·
August 4, 2025
BETHLEHEM, Pa., Aug. 04, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OTI”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced that Anne Messing has joined OTI as Chief Commercial …